Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TransMedics Group, Inc. filings document a Nasdaq-listed medical technology company built around the Organ Care System, National OCS Program and related transplant logistics services for lung, heart and liver transplantation. Its 8-K reports furnish operating results, guidance, tax valuation allowance disclosures and business drivers such as OCS case utilization, logistics revenue and aircraft assets.
Other filings cover material agreements, including headquarters facilities and completed aircraft acquisitions, as well as executive transitions, compensatory arrangements, inducement awards and proxy-governance matters. The company's disclosures also describe its common stock listing, board and shareholder voting matters, executive compensation, clinical program updates and FDA-related device disclosures.
TransMedics Group, Inc. Chief Commercial Officer Giovanni Cecere reported equity awards consisting of stock options and restricted stock units. He was granted options to purchase 16,734 shares of common stock at an exercise price of $0.00 per share and 11,082 restricted stock units, each representing one share of common stock.
The option award vests as to 25% of the underlying shares on February 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. The RSU grant reflects additional direct equity-based compensation tied to the company’s stock.
TransMedics Group, Inc. filed an amended insider ownership report for Chief Commercial Officer Giovanni Cecere. The filing shows he beneficially holds 7,975 restricted stock units (RSUs), each representing a contingent right to receive one share of TransMedics common stock.
These RSUs are reported as directly owned and reflect an equity award rather than an open-market stock purchase or sale. The disclosure updates the market on Cecere’s initial equity-based holdings in the company.
TransMedics Group, Inc. filed an initial ownership report for executive Giovanni Cecere, who serves as Chief Commercial Officer. This Form 3 states that no securities are beneficially owned, meaning Cecere reports holding no TransMedics Group stock or derivative securities as of the event date.
TransMedics Group, Inc. announced leadership transitions in its commercial and legal functions. The Board appointed Giovanni Cecere as Chief Commercial Officer effective February 2, 2026, succeeding Tamer Khayal, M.D., who will become Senior Vice President of International on the same date.
The Board also appointed Matthew Forsyth as Senior Vice President, General Counsel & Corporate Secretary effective March 9, 2026 or his actual start date. Current General Counsel Anil Ranganath will move to a non-executive employee role until June 7, 2026 and then serve as a non-employee consultant until September 7, 2026. His equity awards will continue to vest during his service, and he will receive an annualized consultant fee of $10,000, plus cash severance equal to 0.75 times his highest recent base salary and bonus, COBRA premiums for up to nine months, and a pro-rated 2026 bonus, subject to a release of claims and ongoing covenants.
TransMedics Group, Inc. has signed a long-term lease with BioMed Realty for approximately 498,286 square feet at 188 Assembly Park Drive in Somerville, Massachusetts, which will become its new headquarters and house research, development, lab, manufacturing, assembly, vivarium, office and related functions. The lease term begins on January 8, 2026, with base rent starting on the later of January 1, 2028 or 24 months after term commencement, and running for 192 months from that rent start date.
Initial annual base rent is approximately $23.9 million, increasing 2% each year over the initial term, and the company is expected to bear about 100% of operating and tax expenses for the premises. TransMedics has provided an approximately $18 million letter of credit as a security deposit and holds two 10-year extension options plus a six-month extension option, all subject to customary conditions. Separately, on January 8, 2026, the company acquired two parcels adjacent to the new site in Somerville for $15.0 million each, plus related costs.
TransMedics Group, Inc. (TMDX) reported an insider equity transaction by its Senior Vice President, General Counsel and Secretary. On 11/25/2025, the officer exercised a stock option for 3,000 shares of common stock at an exercise price of $93.88 per share and then sold 3,000 shares of common stock at a weighted average price of $145.22 per share. After these transactions, the officer beneficially owned 13,955 shares of TransMedics common stock directly and held 7,420 stock options directly. The option referenced vested 25% on June 5, 2024 and will continue to vest in equal monthly installments over three years thereafter, subject to continued service.
TransMedics Group, Inc. (TMDX) President & CEO and director Waleed H. Hassanein reported an open-market purchase of company stock. On 11/17/2025, a related revocable trust acquired 8,775 shares of TransMedics common stock at a price of $114 per share. Following this transaction, the trust held 495,009 shares indirectly, while 121,424 shares were held directly in his name. This filing reflects an increase in the insider’s total beneficial ownership of TransMedics shares.
TransMedics Group (TMDX) Form 4: A director exercised 4,142 stock options at $0.70 on 10/29/2025 and sold 4,142 common shares at $130.45 the same day under a Rule 10b5-1 trading plan entered on November 6, 2024. After these transactions, the director directly owned 2,866 shares. The option was fully vested and carried a stated expiration of 02/16/2026, with zero derivative securities remaining afterward.
TransMedics Group (TMDX) reported strong third-quarter results. Total revenue rose to $143.8 million, up from $108.8 million a year ago, with net income of $24.3 million versus $4.2 million last year. Gross profit reached $84.6 million, reflecting higher product and service activity across the Organ Care System (OCS) platform.
Growth was concentrated in the United States, where OCS transplant revenue totaled $139.0 million, led by liver at $107.9 million and heart at $27.4 million. Diluted EPS was $0.66 (basic $0.71). Year‑to‑date, revenue was $444.7 million with $84.9 million of net income and $158.3 million in cash from operations.
The balance sheet strengthened with $466.2 million in cash and $355.2 million in stockholders’ equity. The company reported $452.1 million net carrying value of its 1.50% convertible senior notes due 2028 and $54.6 million in long‑term bank debt. As of October 17, 2025, 34,174,325 common shares were outstanding.
TransMedics Group, Inc. (TMDX) furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company specifies the information is being furnished, not filed, meaning it is not subject to Section 18 liability and will only be incorporated into other filings if expressly referenced. The common stock trades on the Nasdaq Global Market under the symbol TMDX.